Almonertinib (HS-10296)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Almonertinib (HS-10296), covering 2024-08-14 to 2024-08-14. Get the full timeline:
Most recent: Clinical Trial Update: Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer [Phase 2]